These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24089445)

  • 21. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
    Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
    Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
    Guan H; Du Y; Han W; Shen J; Li Q
    Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies.
    Prével C; Pellerano M; González-Vera JA; Henri P; Meunier L; Vollaire J; Josserand V; Morris MC
    Biosens Bioelectron; 2016 Nov; 85():371-380. PubMed ID: 27203461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
    Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
    J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
    Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
    J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
    Bachmann IM; Straume O; Akslen LA
    Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
    Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
    Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human sulfatase 1 exerts anti-tumor activity by inhibiting the AKT/ CDK4 signaling pathway in melanoma.
    Lou X; Sun B; Song J; Wang Y; Jiang J; Xu Y; Ren Z; Su C
    Oncotarget; 2016 Dec; 7(51):84486-84495. PubMed ID: 27806323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK4/6 inhibition triggers anti-tumour immunity.
    Goel S; DeCristo MJ; Watt AC; BrinJones H; Sceneay J; Li BB; Khan N; Ubellacker JM; Xie S; Metzger-Filho O; Hoog J; Ellis MJ; Ma CX; Ramm S; Krop IE; Winer EP; Roberts TM; Kim HJ; McAllister SS; Zhao JJ
    Nature; 2017 Aug; 548(7668):471-475. PubMed ID: 28813415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
    Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
    Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
    Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
    Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
    Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
    Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
    Al-Khalaf HH; Hendrayani SF; Aboussekhra A
    Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
    Serrano M; Hannon GJ; Beach D
    Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.